Application of substance for increasing content or activity of SOX5 in preventing aging and treating aging-related degenerative diseases

By increasing the content or activity of SOX5, the treatment difficulties of aging-related degenerative diseases are solved, significantly delaying cellular aging and improving biological activity, and providing a new strategy for diseases such as osteoarthritis.

CN119055743APending Publication Date: 2024-12-03INST OF ZOOLOGY CHINESE ACAD OF SCI +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410470426.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-31
Filing Date
2024-04-18
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art is difficult to effectively prevent and treat degenerative diseases related to aging, especially the lack of radical clinical means for neurodegenerative diseases, tissue fibrosis and osteoarthritis.

Method used

By providing SOX5 (SRY-Box Transcription Factor5) or substances that increase SOX5 content or activity, it is used to promote SOX5 gene expression or use SOX5 agonists to delay cellular aging and improve symptoms of aging-related diseases.

Benefits of technology

It significantly delays the aging of mesenchymal precursor cells and chondrorist stem cells, improves biological activity, improves the expression of aging-related genes and inflammatory factors, and effectively treats and prevents aging-related degenerative diseases such as osteoarthritis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004798742710000011
    Figure HDA0004798742710000011
  • Figure HDA0004798742710000012
    Figure HDA0004798742710000012
  • Figure HDA0004798742710000013
    Figure HDA0004798742710000013
Patent Text Reader

Abstract

The invention discloses an application of a substance for increasing the content or activity of SOX5 in preventing senescence and treating senescence-related degenerative diseases. The invention finds that SOX5 or a substance for increasing the content or activity of SOX5 has a clear effect in delaying senescence and treating osteoarthritis diseases, and has a clear effect in delaying senescence of mesenchymal precursor cells, mesenchymal stem cells and cartilage stem cells, and the mesenchymal stem cells are an important progenitor cell source of cartilage cells. The invention provides a new strategy for developing gene therapy for delaying senescence and osteoarthritis diseases, and enlarges the selectable range of clinical gene therapy and drug therapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the application of a substance for increasing the content or activity of SOX5 in the prevention of aging and the treatment of aging-related degenerative diseases in the field of biomedicine. Background Art

[0002] Aging is a complex biological process of functional decline of the body. Cells, as the smallest functional units of tissues and organs, also age with age. Cell senescence exhibits characteristics such as self-proliferation blockage and changes in cellular and molecular functions. Senescent cells continue to accumulate in tissues and organs and release a large number of inflammatory factors, which are called senescence-associated secretory phenotype (SASP). The production of SASP induces senescence of surrounding normal cells and deteriorates the tissue microenvironment. These factors together lead to impaired normal functions of tissues and organs and induce aging-related diseases. Therefore, cell senescence is the root cause of tissue and organ aging and individual aging. Stem cells are a type of cell with self-renewal ability and differentiation potential. They play a key role in maintaining the structure and function of tissues and organs, responding to tissue damage and repairing, and are the source of tissue and organ regeneration and the foundation of homeostasis maintenance. However, stem cells in tissues age with age, which is manifested as a decrease in the number of stem cells, impaired regeneration ability and differentiation potential, leading to imbalance of tissue homeostasis and the occurrence of a series of aging-related diseases.

[0003] In recent years, as people's understanding of the biology of aging has gradually deepened, researchers have developed a series of organ / individual aging intervention methods: targeted removal of senescent cells, reducing tissue inflammation levels and extending the lifespan of mice; small molecule drugs delay (stem) cell aging and promote tissue regeneration; gene therapy targets aging-related genes and restores tissue function.

[0004] Common aging-related diseases include neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, etc.), tissue fibrosis (liver, kidney, lung, muscle), osteoarthritis caused by cartilage degeneration, etc. Neurodegenerative diseases are cognitive impairment caused by the loss of neuronal structure and function, including neuronal death. Common aging-related neurodegenerative diseases include Alzheimer's disease (AD) and Parkinson's disease (PD). With age, neurons, microglia, astrocytes and endothelial cells gradually age, and the accumulation of senescent cells is an important source of neuroinflammation. The abnormal function of senescent cells (such as DNA damage and mitochondrial dysfunction) accelerates the death of nerve cells, further promoting the development of the disease. At present, there is no clinical cure for aging-related neurodegenerative diseases. Therefore, promoting neuronal regeneration and replacing senescent nerve cells is a new strategy for treating this type of disease. It has been reported that gene therapy can deliver PGC1-α factor to the brain, reduce β-amyloid protein deposition in AD brains, and improve cognitive function. Gene therapy delivers the AADC factor to the brains of PD patients, restoring the brain's ability to convert L-dopamine into dopamine and improving control of motor symptoms.

[0005] Tissue fibrosis is scarring and tissue hardening caused by excessive deposition of extracellular matrix proteins due to continuous tissue response to injury, accompanied by chronic inflammatory response of macrophages and immune cells infiltration. Fibrosis is a type of aging-related disease (such as liver fibrosis, lung fibrosis, kidney fibrosis and muscle fibrosis, etc.). Liver fibrosis is specifically manifested as the regeneration of liver cells after repeated destruction, diffuse excessive deposition and abnormal distribution of extracellular matrix such as collagen, glycoproteins, proteoglycans in the liver, which is the pathological repair response of the liver to chronic injury. Liver fibrosis is histologically reversible, but it may develop into cirrhosis without treatment. The only treatment for cirrhosis is liver transplantation, but due to the shortage of donors, most patients cannot get good treatment. Therefore, the period of liver fibrosis is a window for treatment. Existing reports have shown that gene therapy can be used to introduce factors such as Foxa1, Foxa2, Foxa3, Gata4, Hnfla and Hnf4a into the liver to alleviate CCL4 (carbon tetrachloride)-induced liver fibrosis. Pulmonary fibrosis is a common degenerative lung disease in the elderly, characterized by the persistent activation of fibroblasts that promote wound healing and fibrosis formation. Delivery of SIRT3 factors through gene therapy can restore the ability to repair fibrotic lung damage and resist fibrosis. Renal fibrosis is caused by inflammatory factors separated by fibroblasts resident in the renal tissue when the renal tissue resists damage. Reducing the level of Mbd2 factors through gene therapy can reduce renal tubular fibrosis.

[0006] Osteoarthritis is a chronic joint disease that is more common in elderly individuals. It is caused by cartilage wear and degeneration, which leads to increased inflammation levels, accompanied by joint pain and deformation. For the treatment of osteoarthritis, non-steroidal anti-inflammatory drugs and weight loss are usually taken to relieve joint pain to a certain extent, but the effect of long-term cure is limited. There is a group of cells with self-renewal ability (cartilage stem / progenitor cells) on the surface of cartilage. When cartilage tissue is damaged, cartilage stem / progenitor cells will differentiate into chondrocytes for repair. In the process of osteoarthritis, cartilage stem / progenitor cells age, causing the regeneration and repair rate of cartilage to be lower than the degeneration rate, resulting in cartilage thinning and lesions, inducing arthritis. It has been reported that gene therapy can be used to introduce factors such as DGCR8, CBX4, YAP1, FOXD1 and CLOCK into the joint cavity, which can slow down the aging of cartilage stem / progenitor cells, promote cartilage regeneration, and restore the physiological function of joints.

[0007] SOX5 is a member of the SRY-Box transcription factor family and plays an important role in embryonic development and cell fate determination. It works with SOX6 and SOX9 at (super) enhancer elements to promote the expression of cartilage development-related genes. Currently, no studies have shown the role of SOX5 in osteoarthritis. Summary of the invention

[0008] The technical problem to be solved by the present invention is how to prevent aging and treat aging-related degenerative diseases.

[0009] In order to solve the above technical problems, the present invention first provides the use of SOX5 (SRY-Box Transcription Factor 5) (GeneID: 6660, updated on April 4, 2023) or a substance that increases the content or activity of SOX5 in the preparation of products for treating and / or preventing and / or delaying aging.

[0010] In one embodiment of the present invention, SOX5 is derived from human, and its sequence is shown in SEQ ID No.2.

[0011] In another embodiment of the present invention, SOX5 is derived from mouse, and its sequence is shown as SEQ ID No.5.

[0012] In the above application, the substance that increases the content or activity of SOX5 may be a substance that promotes the expression of the SOX5 gene or a biological material related to SOX5;

[0013] The biological material is any one of the following B1) to B4):

[0014] B1) Nucleic acid molecule encoding SOX5;

[0015] B2) an expression cassette containing the nucleic acid molecule described in B1);

[0016] B3) a recombinant vector containing the nucleic acid molecule described in B1), or a recombinant vector containing the expression cassette described in B2);

[0017] B4) A recombinant microorganism containing the nucleic acid molecule described in B1), or a recombinant microorganism containing the expression cassette described in B2), or a recombinant microorganism containing the recombinant vector described in B3).

[0018] The nucleic acid molecule may be DNA, such as cDNA, genomic DNA or recombinant DNA; the nucleic acid molecule may also be RNA, such as mRNA or hnRNA.

[0019] In one embodiment of the present invention, the nucleic acid molecule described in B1) is as shown in SEQ ID No.1.

[0020] In another embodiment of the present invention, the nucleic acid molecule described in B1) is as shown in SEQ ID No.4.

[0021] In the above applications, the vector may be a plasmid, a cosmid, a phage or a viral vector.

[0022] B3) The recombinant vector may be a recombinant vector PLE4-SOX5 or PLE4-mSOX5 obtained by connecting the full-length cDNA sequence of SOX5 (such as SEQ ID No.1 or SEQ ID No.4 in the sequence list) to a PLE4 vector double-digested with BamHI and MluI. PLE4-SOX5 is a recombinant vector obtained by replacing the DNA fragment between the BamHI and MluI recognition sequences of the PLE4 vector with the DNA fragment shown in SEQ ID No.1. PLE4-mSOX5 is a recombinant vector obtained by replacing the DNA fragment between the BamHI and MluI recognition sequences of the PLE4 vector with the DNA fragment shown in SEQ ID No.4.

[0023] In the above applications, the microorganism may be yeast, bacteria, algae or fungi.

[0024] In the above application, the substance that promotes the expression of the SOX5 gene can be a CRISPR / dCas9 transcription activation system that targets the transcription start site of the SOX5 gene.

[0025] The CRISPR / dCas9 transcription activation system targeting the transcription start site of the SOX5 gene includes a sgRNA plasmid (such as a lentiviral plasmid sgSOX5-human) that can specifically promote the transcription of the SOX5 gene obtained by inserting a gene fragment targeting the transcription start site (TSS) of the SOX5 gene into a lentiSAMv2 vector, and a lentiviral packaging vector psPAX2 and pMD2G to obtain a sgSOX5-human lentivirus. The lentiviral plasmid sgSOX5-human is obtained by connecting an sgRNA sequence (such as GTCAGTTGATTAGATTTTCTG and / or GTCTGGAAATGGAGCAGACAA) targeting the transcription start site of the SOX5 gene to a lentiSAMv2 vector obtained by Esp3I digestion.

[0026] In the above application, the substance that increases the content or activity of SOX5 may be a SOX5 agonist.

[0027] In the above application, the aging may be replicative aging, and / or pathological aging due to adult progeria or childhood progeria.

[0028] The pathological aging may be aging caused by human progeria gene mutation (such as LMNA gene mutation) and / or adult progeria gene mutation (such as WRN gene mutation). Further, the pathological aging may be aging caused by mesenchymal precursor cells with human progeria gene mutation and / or adult progeria gene mutation.

[0029] The replicative senescence may be senescence caused by cell replication.

[0030] In the above application, the aging refers to the aging of animal cells, tissues, organs or individuals.

[0031] Further, the senescence of the cells may be the senescence of mesenchymal precursor cells or mesenchymal stem cells or cartilage stem / progenitor cells. The senescence of the mesenchymal precursor cells or mesenchymal stem cells may be pathological senescence or replicative senescence caused by human progeria gene mutation and / or adult progeria gene mutation. The tissue may be cartilage tissue.

[0032] The aging of the individual may be natural aging.

[0033] The treatment and / or prevention of aging can be reflected in promoting cell proliferation and / or reducing inflammation levels and / or improving the expression of aging markers (such as SA-β-gal), aging-related genes (such as CDKN2A, CDKN1A, LMNB1, TMPO), SASP-related genes (such as IL-6, CXCL8) and / or progeria markers (such as Progerin).

[0034] The cells may be mesenchymal precursor cells or mesenchymal stem cells with mutations in human progeria-causing genes (such as WRN gene) and / or mutations in adult progeria-causing genes (such as LMNA gene) and / or replicative senescence.

[0035] The animal may be a mammal, such as a human or a mouse.

[0036] The present invention also provides the use of SOX5 or the substance that increases the content or activity of SOX5 in the preparation of products that increase the biological activity of animal cells, tissues, organs or individuals.

[0037] In the above application, the tissue may be cartilage tissue.

[0038] The improvement in the biological activity can be reflected in the improvement of animal athletic ability, the reduction of senescent cells and / or inflammatory cells, the increase in cartilage thickness, the increase in the expression of genes that promote cartilage development, collagen and proteoglycan formation, regeneration-related genes (such as Yap1), cartilage development-related genes (such as Sox9, Acan) and extracellular matrix-related genes (such as Col2a1, Col11a1), and / or the decrease in the expression of genes involved in immune response regulation, NF-κB, and oxidative stress-related signaling pathways.

[0039] The present invention also provides the use of SOX5 or the substance that increases the content or activity of SOX5 in the preparation of products for treating aging-related degenerative diseases (such as osteoarthritis, neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease, etc.), and fibrosis of tissues such as liver, kidney, lung, and muscle).

[0040] The present invention also provides a product, wherein the active ingredient of the product is SOX5 or the substance that increases the content or activity of SOX5.

[0041] The product can be used to treat and / or prevent aging, improve the biological activity of animal cells, tissues, organs or individuals, or treat aging-related degenerative diseases.

[0042] The experiments of the present invention confirm that SOX5 or substances that increase the content or activity of SOX5 have a clear effect in delaying aging and treating osteoarthritis, and have a clear effect in delaying the aging of mesenchymal precursor cells, mesenchymal stem cells and cartilage stem cells, and mesenchymal stem cells are an important source of progenitor cells for cartilage cells. The present invention provides a new strategy for developing gene therapy for delaying aging and osteoarthritis, and expands the range of options for clinical gene therapy and drug therapy.

[0043] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] Figure 1 To identify genes that delay cell senescence by genome-wide CRISPR activation screening in WS mesenchymal progenitor cells. (A) Cell morphology (left) and monoclonal formation ability were used to detect the proliferation ability of cells infected with the SAMv2 lentiviral library. (B) Immunofluorescence detection of the proportion of Ki67-positive cells in cells infected with the SAMv2 lentiviral library. (C) SA-β-gal staining was used to detect the proportion of senescent cells after infection with the SAMv2 lentiviral library. In AC, Control indicates infection with sgNTC lentiviral concentrate, and SAM library indicates infection with the SAMv2 lentiviral library. (D) Bioinformatics analysis of genes enriched during the two screening repetitions. The red dots indicate the 9 genes enriched in both repeated experiments. (E) SA-β-gal staining was used to detect the proportion of senescent cells after infection with the lentivirus corresponding to the top 9 genes. Cells infected with sgNTC virus were used as the control, and the fold change of the positive cell proportion was taken as log2.

[0045] Figure 2Activation of the SOX5 gene can delay the senescence phenotype of mesenchymal progenitor cells carrying the human progeria gene mutation. (A) Real-time fluorescence quantitative PCR (chain polymerase reaction) was used to detect the transcription level of SOX5 in cells infected with sgSOX5-human lentivirus. (B) Western Blot was used to detect the content of SOX5 protein in cells infected with sgSOX5-human lentivirus. (C) Immunofluorescence was used to detect the proportion of Ki67-positive cells in cells infected with sgSOX5-human lentivirus. (D) SA-β-gal staining was used to detect the proportion of senescent cells in cells infected with sgSOX5-human lentivirus. (E) Real-time fluorescence quantitative PCR (chain polymerase reaction) was used to detect the transcription levels of CDKN2A, CDKN1A, IL-6, LMNB1 and TMPO in cells infected with sgSOX5-human lentivirus. sg-NTC indicates cells infected with sgNTC lentivirus, and sg-SOX5 indicates cells infected with sgSOX5-human lentivirus. The scale bar in (C) is 20 μm; the scale bar in (D) is 200 μm.

[0046] Figure 3 Increasing the content of SOX5 can delay the accelerated senescence phenotype of mesenchymal progenitor cells carrying the human progeria gene mutation. (A) Western Blot detection of SOX5 protein content in cells infected with PLE4-SOX5 virus. (B) Immunofluorescence staining to detect the proportion of ki67-positive cells in cells infected with PLE4-SOX5 lentivirus. (C) SA-β-gal staining to detect the proportion of senescent cells in cells infected with PLE4-SOX5 lentivirus. (D) Real-time fluorescence quantitative PCR (chain polymerase reaction) to detect the transcription levels of CDKN2A, CDKN1A, IL-6, LMNB1 and TMPO in cells infected with PLE4-SOX5 lentivirus. GAL4 indicates cells infected with PLE4-GAL4 virus, and SOX5 indicates cells infected with PLE4-SOX5 virus. The scale bar in Figure (B) is 20μm; the scale bar in Figure (C) is 200μm.

[0047] Figure 4Increasing the SOX5 content can delay the replicative senescence phenotype of human mesenchymal progenitor cells. (A) Western Blot detection of SOX5 protein content in cells infected with PLE4-SOX5 virus. (B) Immunofluorescence staining to detect the proportion of ki67-positive cells in cells infected with PLE4-SOX5 lentivirus. (C) SA-β-gal staining to detect the proportion of senescent cells in cells infected with PLE4-SOX5 lentivirus. (D) Western Blot detection of P16, P21, LaminB1, and LAP2 protein content in cells infected with PLE4-SOX5 virus. GAL4 indicates cells infected with PLE4-GAL4 virus, and SOX5 indicates cells infected with PLE4-SOX5 virus. The scale bar in Figure (B) is 20μm; the scale bar in Figure (C) is 200μm.

[0048] Figure 5 Increasing the SOX5 content can delay the accelerated senescence phenotype of mesenchymal progenitor cells carrying the human progeria gene mutation. (A) Western Blot detection of SOX5 protein content in cells infected with PLE4-SOX5 virus. (B) Immunofluorescence staining to detect the proportion of ki67-positive cells in cells infected with PLE4-SOX5 lentivirus. (C) SA-β-gal staining to detect the proportion of senescent cells in cells infected with PLE4-SOX5 lentivirus. (D) Western Blot detection of P16, P21, LaminB1, and LAP2 protein content in cells infected with PLE4-SOX5 virus. (E) Immunofluorescence staining to detect the content of progerin in cells infected with PLE4-SOX5 lentivirus. GAL4 indicates cells infected with PLE4-GAL4 virus, and SOX5 indicates cells infected with PLE4-SOX5 virus. The scale bars in Figures (B) and (E) are 20 μm; the scale bar in Figure (C) is 200 μm.

[0049] Figure 6To increase the content of SOX5 in relieving osteoarthritis in aged mice. (A) Schematic diagram of evaluating the therapeutic effect of SOX5 on osteoarthritis in aged mice. (B) After injection of PLE4-mSOX5 virus, the pulling force of the mouse hind limb was detected. (C) Immunohistochemical staining was used to detect the proportion of SOX5-positive cells in the articular cartilage of mice injected with PLE4-mSOX5 virus. (D) Micro-CT was used to detect the osteophyte hyperplasia in the joints of mice injected with PLE4-mSOX5 virus. (E) Safranin fast green staining was used to detect the area of ​​articular cartilage in mice injected with PLE4-mSOX5 virus. (F) HE staining was used to detect the synovial hyperplasia in the joints of mice injected with PLE4-mSOX5 virus. (G) Immunohistochemical staining was used to detect the proportion of P21-positive cells in the articular cartilage of mice injected with PLE4-mSOX5 virus. (H) Immunohistochemical staining was used to detect the proportion of MMTV-positive cells in the articular cartilage of mice injected with PLE4-mSOX5 virus. (I) Immunohistochemical staining was used to detect the proportion of IL-6 positive cells in the articular cartilage of mice injected with PLE4-mSOX5 virus. (J) Immunohistochemical staining was used to detect the proportion of TNFα positive cells in the articular cartilage of mice injected with PLE4-mSOX5 virus. (K) Immunohistochemical staining was used to detect the proportion of Aggrecan positive cells in the articular cartilage of mice injected with PLE4-mSOX5 virus. (L) Immunohistochemical staining was used to detect the proportion of MMP13 positive cells in the articular cartilage of mice injected with PLE4-mSOX5 virus. (M) Real-time fluorescence quantitative PCR (chain polymerase reaction) was used to detect the transcription levels of Cd5l, Ccr2, S100a8 and S100a9 genes in the articular cartilage of mice injected with PLE4-mSOX5 virus. (N) Real-time fluorescence quantitative PCR (chain polymerase reaction) was used to detect the transcription levels of Yap1, Sox9, Acan, Col2a1 and Col11a1 genes in the articular cartilage of mice injected with PLE4-mSOX5 virus. The scale bars in (E) and (F) are 40 μm (upper panel) and 10 μm (lower panel); the scale bars in (C) and (GL) are 40 μm (upper panel) and 5 μm (lower panel). GAL4 indicates mice injected with PLE4-GAL4 virus, and mSOX5 indicates mice injected with PLE4-mSOX5 virus.

[0050] Figure 7To investigate the effect of increasing SOX5 content on alleviating the anterior cruciate ligament transection (ACLT) osteoarthritis model. (A) Schematic diagram of evaluating the therapeutic effect of SOX5 on the ACLT osteoarthritis model. (B) Immunohistochemical staining was used to detect the proportion of SOX5-positive cells in the articular cartilage of mice injected with PLE4-mSOX5 virus. (C) Micro-CT was used to detect the osteophyte hyperplasia in the joints of mice injected with PLE4-mSOX5 virus. (D) Safranin fast green staining was used to detect the OARSI score of the joints of mice injected with PLE4-mSOX5 virus. (E) HE staining was used to detect the synovial hyperplasia in the joints of mice injected with PLE4-mSOX5 virus. (F) Immunohistochemical staining was used to detect the proportion of Aggrecan-positive cells in the articular cartilage of mice injected with PLE4-mSOX5 virus. (G) Immunohistochemical staining was used to detect the proportion of MMP13-positive cells in the articular cartilage of mice injected with PLE4-mSOX5 virus. (H) Immunohistochemical staining was used to detect the proportion of IL-6 positive cells in the articular cartilage of mice injected with PLE4-mSOX5 virus. The scale bars in (D) and (E) are 40 μm (upper panel) and 10 μm (lower panel); the scale bars in (F, G, and H) are 40 μm (upper panel) and 5 μm (lower panel). Sham indicates sham operation group, GAL4 indicates mice injected with PLE4-GAL4 virus, and mSOX5 indicates mice injected with PLE4-mSOX5 virus. DETAILED DESCRIPTION

[0051] The experimental methods in the following examples, unless otherwise specified, are conventional methods, and are carried out according to the techniques and conditions described in the literature published in the art or according to the product instructions. The materials, reagents, instruments, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources. The quantitative tests in the following examples were set up for three replicates. All animal experiments were approved by the Animal Welfare Committee of the Institute of Zoology, Chinese Academy of Sciences. The experimental data are expressed as mean ± standard deviation and analyzed using GraphPad Prism 9 statistical software. P < 0.05 is considered to be significantly different between groups.

[0052] Human embryonic kidney cell line 293T cells: ATCC product, catalog number CRL-3216.

[0053] 293T cell culture medium: 89% DMEM high glucose medium (Hyclone), 10% fetal bovine serum (Gibco, 10100-147), 1% penicillin / streptomycin (Invitrogen, 15070-063).

[0054] Mesenchymal precursor cell culture medium (i.e., MPC culture medium): 88% α-MEM+GlutaMAX (Invitrogen, 12571071), 10% fetal bovine serum (Gemini, 900-108), 1% non-essential amino acids (Invitrogen, 11140-050), 1% penicillin / streptomycin (Invitrogen, 15070-063), recombinant human fibroblast growth factor (JPC, 100120) was added and its concentration in the system was 1 ng / ml.

[0055] The WS (Werner Syndrome) mesenchymal precursor cells (i.e., mesenchymal precursor cells carrying human progeria gene mutations) in the following embodiments are mesenchymal stem cells with WRN function loss in the Chinese patent (pluripotent stem cells carrying human progeria gene mutations and preparation method, ZL201510137846.4). The public can obtain the biomaterial from the applicant. The biomaterial is only used to repeat the relevant experiments of the present invention and cannot be used for other purposes.

[0056] The HGPS (Hutchinson Giford Progeria Syndrome) mesenchymal precursor cells (i.e., human progeria mesenchymal precursor cells) in the following examples are mesenchymal stem cells derived from human progeria patients in the Chinese patent (Application of Oltipraz in Reversing the Aging Phenotype of Human Progeria, ZL201610265387.2), which are derived from in vitro directed differentiation of HGPS-iPSCs, and the preparation steps are as follows:

[0057] iPSCs (HGPS-iPSCs) derived from HGPS patients, in which the LMNA gene was mutated (LMNA genomic sequence is GenBank: NG_008692.2; cDNA sequence is GenBank: NM_170707.3), the mutation type is C1824T (GGCGG mutates to GGTGG), and the reference sequence of this site is the CDS region in the LMNA cDNA sequence GenBank: NM_170707.3.

[0058] HGPS-iPSCs were differentiated into embryoid bodies (EBs) for 14 days, and EBs were inoculated into 6-well plates coated with matrigel for culture for 2 weeks until fibrous cells appeared. After another passage, flow cytometry was used to sort the cell populations that were positive for CD73, CD90, and CD105, which were mesenchymal stem cells derived from human progeria patients (referred to as HGPS-MSCs).

[0059] Among them, iPSCs derived from HGPS patients (referred to as HGPS-iPSCs) are recorded in "Liu, GH, Barkho, BZ, Ruiz, S., Diep, D., Qu, J., Yang, SL, Panopoulos, AD, Suzuki, K., Kurian, L., Walsh, C., et al. (2011a). Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 472, 221-225." The public can obtain them from the applicant for use only in repeating the experiments of the present invention.

[0060] The fluorescently labeled antibodies used for flow cytometry sorting of MSCs are as follows:

[0061] FITC-labeled anti-human cell surface recognition molecule CD90 antibody, BD Biosciences, catalog number: 555595.

[0062] Fluorescein PE-labeled anti-human cell surface recognition molecule CD73 antibody, BD Biosciences, catalog number: 550257.

[0063] Fluorescein APC-labeled anti-human cell surface recognition molecule CD105 antibody, BD Biosciences, catalog number: 17-1057-42.

[0064] Fluorescein APC labeled isotype control antibody, BD Biosciences, catalog number: 555751.

[0065] Fluorescein PE labeled isotype control antibody, BD Biosciences, catalog number: 555749.

[0066] Fluorescein FITC-labeled isotype control antibody, BD Biosciences, catalog number: 555742.

[0067] Mesenchymal progenitor cells were prepared using human embryonic stem cell H9 cell line (WiCell product, catalog number: WA09(H9)-DL-7), and the specific steps are as follows:

[0068] (1) Differentiating human embryonic stem cells H9 cells into embryoid bodies to obtain embryoid bodies;

[0069] (2) culturing the embryoid bodies obtained in step (1) until fibrous cells appear;

[0070] (3) After completing step (2), collecting cells, subculturing and culturing;

[0071] (4) After completing step (3), cells that are positive for CD73, CD90, and CD105 are sorted, which are mesenchymal precursor cells.

[0072] Mesenchymal progenitor cells were cultured as follows: Mesenchymal progenitor cells were cultured in the above-mentioned mesenchymal progenitor cell culture medium and subcultured every 4-5 days. 5 Cells were seeded into 6-well plates at a density of 100 cells / well.

[0073] In the following examples, the SA-β-gal staining steps for detecting cell senescence are as follows:

[0074] SA-β-gal (senescence-associated β-galactosidase) is a hydrolase in lysosomes. Its activity increases in aged cells. When the substrate X-Gal is added, the hydrolase can catalyze the decomposition of X-Gal and make the cells appear blue. Therefore, SA-β-gal has become a "gold standard" for rapid detection of cell aging. The specific method is as follows:

[0075] 1) 1×10 5 Cell / well density Mesenchymal progenitor cells were seeded into sigma-coated 6-well plates and stained when the cell density reached 80% (day 3).

[0076] 2) After completing step 1), fix the cells with fixative (2% (volume percentage, v / v) formaldehyde + 0.2% (volume percentage, v / v) glutaraldehyde + 97.8% (volume percentage, v / v) PBS) for 4 minutes (must not exceed 5 minutes), and wash twice with PBS.

[0077] 3) After completing step 2), add 2 mL of staining solution (40 mM citric acid / sodium phosphate buffer, 5 mM K4[Fe(CN)6], 5 mM K3[Fe(CN)6], 150 mM NaCl, 2 mM MgCl2, 1 mg / mL X-gal) to each well and incubate in a 37°C constant temperature incubator in the dark overnight.

[0078] 4) After completing step 3), wash twice with PBS, observe under an inverted microscope, take pictures and count.

[0079] Example 1: Screening for genes that delay aging phenotypes in mesenchymal progenitor cells carrying human progeria gene mutations.

[0080] This example uses CRISPR whole genome activation screening to discover several genes that delay the accelerated aging of mesenchymal progenitor cells carrying human progeria gene mutations, among which 9 genes were verified to have the phenotype of delaying cell aging.

[0081] Preparation of a genome-wide CRISPR activation screening lentiviral library

[0082] The whole genome CRISPR activation (CRISPRa) screening plasmid library, SAMv2 plasmid library (1000000078) was purchased from Addgene. This plasmid library contains 70290 sgRNA recombinant plasmids, which target the TSS sites of 23432 protein genes in the whole genome and promote gene transcription with the assistance of transcription activators p65 and HSF1. The recombinant plasmid is constructed based on the LentiSAMv2 vector (Addgene product, #75112). The transcription activators p65 and HSF1 are encoded by the lentiMPHv2 vector (Addgene product, #89308).

[0083] The SAM plasmid library was co-transfected with the lentiviral packaging vector psPAX2 (Addgene product, #12260) and pMD2.G (Addgene product, #12259) into 293T cells to obtain the CRISPR-activated lentiviral library. The steps are as follows:

[0084] 1.1 The SAMv2 plasmid library, lentiviral packaging vector psPAX2 and pMD2G were co-transfected into 293T cells using the Lipo3000 transfection kit (Thermo Scientific) (ratio: 1 10 cm dish of 293T cells: 9 μg SAMv2 plasmid library, 6 μg psPAX2 and 3 μg pMD2.G) and incubated in a 37°C incubator.

[0085] 1.2 After 8 hours of culture, replace with fresh 293T cell culture medium and continue to culture for 48-54 hours.

[0086] 1.3 Collect the culture medium supernatant, filter it with a 0.45 μm pore size filter membrane, and collect the filtrate.

[0087] 1.4 Centrifuge at 19,400 rpm for 2 hours at 4°C, discard the supernatant, and resuspend in mesenchymal precursor cell culture medium to obtain the lentiviral concentrate containing the whole genome CRISPR activation screening plasmid library, referred to as SAMv2 lentiviral library.

[0088] 2. Preparation of control group lentiviral CRISPRa vector

[0089] 2.1 The sgRNA sequence of the control group does not target any gene locus, and the sequence is as follows:

[0090] sgNTC-F: 5'-CACCGCTGAAAAAGGAAGGAGTTGA-3';

[0091] sgNTC-R: 5'-AAACTCAACTCCTTTCCTTTTTCAGC-3'.

[0092] The above oligonucleotide sequence without targeting specificity was synthesized in a company (Tsingke). sgNTC-F and sgNTC-R were annealed to obtain sgNTC, which was ligated to the lentiSAMv2 vector obtained by Esp3I (Thermo Scientific) digestion using T4 DNA ligase (NEB) to obtain a recombinant vector with the correct sequence, which was recorded as sgNTC lentiviral CRISPRa vector.

[0093] 2.2 According to steps 1.1-1.4, replace the SAMv2 plasmid library with the sgNTC lentiviral CRISPRa vector and the lentiMPHv2 vector to obtain the sgNTC lentiviral concentrate and the MPHv2 lentiviral concentrate, respectively.

[0094] 3. Infect mesenchymal progenitor cells with SAMv2 lentivirus and screen for genes that delay the accelerated aging phenotype of mesenchymal progenitor cells carrying human progeria gene mutations.

[0095] 3.1 Inoculate the culture dish with WS mesenchymal progenitor cells of passage 4 (1×10 6 10 μl of MPHv2 lentivirus concentrate and 20 μl of Polybrene (1:1000) were added to cells / 15 cm culture dish. After 48 hours, fresh culture medium containing hygromycin (2.5 μg / ml) was added. After 6 days, normal culture medium was replaced. After passaging, sufficient MPH-transfected cells were obtained, referred to as MPH-WS mesenchymal precursor cells.

[0096] 3.2-way 3×10 7 MPH-WS mesenchymal precursor cells (1×10 6cells / 15cm culture dish), add 4μl SAMv2 lentiviral library (or sgNTC lentiviral concentrate) and 20μl Polybrene (1:1000), add fresh culture medium containing blasticidin (5μg / ml) after 48 hours, and replace with normal culture medium after 6 days. After continuous passage for about 20 days, cells infected with SAMv2 lentiviral library began to appear clone-like cells and gradually proliferated. After continuous culture for about 6 weeks, cells infected with sgNTC lentiviral concentrate showed growth stagnation and cell enlargement. Cell proliferation molecular markers (Ki67) and cell senescence markers (SA-β-gal) were detected, and cells infected with SAMv2 lentiviral concentrate were collected. The sgRNA in these cells with improved proliferation ability was enriched and analyzed with the help of second-generation sequencing and bio-confidence analysis.

[0097] Blasticidin is a product of Invivogene, with the product number ant-bl-1;

[0098] Hygromycin is a product of Invivogene, and the product number is ant-hg-1.

[0099] Results of cell morphology, cell proliferation ability and senescence level detection ( Figure 1 ) showed that after infection with the SAMv2 lentiviral library, the cell volume became smaller ( Figure 1 In the middle A), the proportion of Ki67 positive cells increased. In the control group infected with sgNTC lentiviral concentrate, almost no positive cells were detected, while in the cells infected with SAMv2 lentiviral library, 17.7% of Ki67 positive cells were detected. Figure 1 B), indicating that increasing the content of certain genes in cells promotes stem cell proliferation. The proportion of SA-β-gal positive cells in cells infected with the SAMv2 lentiviral library decreased, 44.9% of cells infected with the sgNTC lentiviral concentrate contained senescent cells, and only 15.2% of cells infected with the SAMv2 lentiviral library contained senescent cells ( Figure 1 C), indicating that increasing the content of certain genes in cells delays stem cell aging.

[0100] Furthermore, by analyzing the information of sgRNA infected in these cells with improved proliferation ability and delayed aging, 9 genes that delay aging of human mesenchymal stem cells were identified ( Figure 1 D), among which SOX5 has the most obvious effect ( Figure 1 Middle E).

[0101] The sgRNA sequences corresponding to SOX5 were obtained from the SAMv2 plasmid library:

[0102] SOX5-sg-1-F: 5'-CACCGTCAGTTGATTAGATTTTCTG-3';

[0103] SOX5-sg-1-R: 5'-AAACCAGAAAATCTAATCAACTGAC-3'.

[0104] SOX5-sg-2-F: 5'-CACCGTCTGGAAATGGAGCAGACAA-3';

[0105] SOX5-sg-2-R: 5'-AAACTTGTCTGCTCCATTTCCAGAC-3'.

[0106] According to step 1, lentiviral concentrates containing the above lentiviral CRISPRa vectors were obtained respectively.

[0107] Example 2: Increasing SOX5 content can delay the accelerated aging phenotype of mesenchymal precursor cells carrying human progeria gene mutations

[0108] This example found that increasing the SOX5 (SRY-Box Transcription Factor 5) content can delay the accelerated aging phenotype of mesenchymal progenitor cells carrying human progeria gene mutations. The experimental steps are as follows:

[0109] Take the lentiviral concentrate containing the recombinant vector of the second sgRNA targeting SOX5 (obtained from SOX5-sg-2-F and SOX5-sg-2-R in Example 1), marked as sgSOX5-huamn lentiviral concentrate. The 4th generation WS mesenchymal precursor cells were used as test cells and infected with sgNTC and sgSOX5-human lentiviral concentrates, respectively. The specific method is: first, add 1.5μl of MPHv2 lentiviral solution and 2μl of Polybrene to the culture well (one well of a 6-well plate) inoculated with the 4th generation WS mesenchymal precursor cells, and add 1μl of sgSOX5-human lentiviral concentrate (or sgNTC lentiviral concentrate) after 24 hours. Change the medium the next day, then culture normally and pass down.

[0110] WS mesenchymal precursor cells infected with sgNTC and sgSOX5-human lentivirus were serially passaged for 3-4 generations, and then the cells were collected to detect the mRNA and protein levels of SOX5, the cell proliferation molecular marker (Ki67), the cell senescence marker (SA-β-gal), the senescence-related genes (CDKN2A, CDKN1A, LMNB1, TMPO) and the SASP-related genes (IL-6).

[0111] The reagent used to detect Ki67 is a product of Zhongshan Jinqiao Company, with the product number ZM-0166.

[0112] The primers for detecting the mRNA levels of SOX5, CDKN2A, CDKN1A, LMNB1, TMPO, and IL-6 are as follows:

[0113] SOX5-F: 5′-ATAAAGCGTCCAATGAATGCCT-3′; SOX5-R: 5′-GCGAGATCCCAATATCTTGCTG-3′;

[0114] CDKN2A-F: 5′-ATGGAGCCTTCGGCTGACT-3′; CDKN2A-R: 5′-GTAACTATTCGGTGCGTTGGG-3′;

[0115] CDKN1A-F: 5′-CGATGGAACTTCGACTTTGTCA-3′; CDKN1A-R: 5′-GCACAAGGGTACAAGACAGTG-3′;

[0116] LMNB1-F: 5′-GAAAAAGACAACTCTCGTCGCA-3′; LMNB1-R: 5′-GTAAGCACTGATTTCCATGTCCA-3′;

[0117] TMPO-F: 5′-CCCCTCGGTCCTGACAAAAG-3′; TMPO-R: 5′-CGCTCTTCGTCACTGGAGAA-3′;

[0118] IL-6-F: 5′-ACTCACCTCTTCAGAACGAATTG-3′; IL-6-R: 5′-CCATCTTTGGAAGGTTCAGGTTG-3′;

[0119] CXCL8-F: 5′-ACTGAGAGTGATTGAGAGTGGAC-3′; CXCL8-R: 5′-AACCCTCTGCACCCAGTTTTC-3′.

[0120] The antibody used to detect SOX5 protein was produced by Abcam, with the catalog number ab94396.

[0121] The antibody used to detect GAPDH protein was produced by Santa Cruz Corporation, and the product number is sc-365042.

[0122] The antibody used to detect P16 protein was produced by BD Biosciences, with the catalog number being 550834.

[0123] The antibody used to detect P21 protein was produced by Cell Signaling Technology, and the product number is 2947s.

[0124] The antibody used to detect LaminB1 protein was produced by Abcam, with the catalog number ab16048.

[0125] The antibody used to detect LAP2 protein was produced by BD Biosciences, with the catalog number being 611000.

[0126] Aging-related marker detection experiment ( Figure 2 ) showed that SOX5 transcription and protein levels were increased in WS mesenchymal progenitor cells infected with sgSOX5-human lentivirus compared with cells infected with sgNTC lentivirus ( Figure 2 AB), indicating that the intracellular SOX5 content increased. The proportion of Ki67-positive cells in cells infected with sgSOX5-human lentivirus increased from 16.5% to 29.9% in sgNTC-infected cells ( Figure 2 C), indicating that increasing the intracellular SOX5 content can promote cell proliferation. The proportion of SA-β-gal positive cells in cells infected with sgSOX5-human lentivirus decreased from 57.5% to 29.1% in sgNTC infected cells ( Figure 2 Middle D); cells infected with sgSOX5-human lentivirus had decreased levels of CDKN2A, CDKN1A, and IL-6, and increased levels of LMNB1 and TMPO ( Figure 2 Middle E) indicates that the increase in intracellular SOX5 content improves the levels of aging-related markers.

[0127] Example 3: Increasing the SOX5 gene content can delay the accelerated aging phenotype of mesenchymal precursor cells carrying human progeria gene mutations

[0128] This example found that increasing the SOX5 (SRY-Box Transcription Factor 5) gene can delay the accelerated aging phenotype of mesenchymal progenitor cells carrying human progeria gene mutations. The experimental steps are as follows:

[0129] 1. Preparation of recombinant lentivirus with increased human SOX5 gene content

[0130] 1.1 Preparation of Lenti-vector for increasing SOX5 gene

[0131] The full-length cDNA sequence of SOX5 was amplified by PCR using the cDNA of WS mesenchymal progenitor cells as a template. The amplification primers are as follows:

[0132] cDNA-SOX5-F: 5'-ATGCTTACTGACCCTGATTTACCTCAGGAG-3';

[0133] cDNA-SOX5-R: 5'-TCAGTTGGCTTGTCCTGCAATATGG-3'.

[0134] The full-length cDNA sequence of SOX5 obtained by PCR amplification (SEQ ID No. 1 in the sequence list, encoding SOX5 shown in SEQ ID No. 2) was connected to the PLE4 vector (whose sequence is shown in SEQ ID No. 6) double-digested with BamHI (NEB) and MluI (NEB), and the recombinant vector with the correct sequence was recorded as the lentiviral recombinant vector PLE4-SOX5, and PLE4-SOX5 can express SOX5 shown in SEQ ID No. 2. Specifically, PLE4-SOX5 is a recombinant vector obtained by replacing the DNA fragment between the BamHI and MluI recognition sequences of the PLE4 vector with the DNA fragment shown in SEQ ID No. 1.

[0135] According to the above method, a control recombinant vector (PLE4-GAL4) with correct sequence was obtained. The primers used are as follows:

[0136] cDNA-GAL4-F: 5'-ATGATGAAGCTACTGTCTTCTATC-3';

[0137] cDNA-GAL4-R: 5'-CTAAACCTTTCTCTTTTTCTTGG-3'.

[0138] PLE4-GAL4 is a recombinant vector obtained by ligating the full-length cDNA sequence of GAL4 obtained by PCR amplification (SEQ ID No. 3 in the sequence list) to a PLE4 vector double-digested with BamHI (NEB) and MluI (NEB), and the recombinant vector can express the GAL4 protein encoded by SEQ ID No. 3. Specifically, PLE4-GAL4 is a recombinant vector obtained by replacing the DNA fragment between the BamHI and MluI recognition sequences of the PLE4 vector with the DNA fragment shown in SEQ ID No. 3.

[0139] 1.2 According to the virus preparation method of "Example 1-Step 1, 1.1-1.4", the "SAMv2 plasmid library" was replaced with "PLE4-SOX5" and "PLE4-GAL4" respectively to obtain PLE4-SOX5 lentiviral concentrate and PLE4-GAL4 lentiviral concentrate.

[0140] 2. PLE4-SOX5 lentivirus infection of WS mesenchymal precursor cells

[0141] The 4th generation WS mesenchymal progenitor cells were used as test cells and infected with PLE4-GAL4 and PLE4-SOX5 lentiviral concentrates, respectively. The specific method is: first, add 1 μl of PLE4-SOX5 lentiviral concentrate (or PLE4-GAL4 lentiviral concentrate) and 2 μL of Polybrene to the culture well (one well of a 6-well plate) inoculated with the 4th generation WS mesenchymal progenitor cells. Change the medium the next day, and then culture and passage normally.

[0142] WS mesenchymal precursor cells infected with PLE4-GAL4 and PLE4-SOX5 lentiviruses were continuously passaged for 3-4 generations, and then the cells were collected to detect the protein level of SOX5, the cell proliferation molecule marker (Ki67), the cell senescence marker (SA-β-gal), the senescence-related genes (CDKN2A, CDKN1A, LMNB1, TMPO) and the levels of SASP-related genes (IL-6, CXCL8). The reagent materials and detection methods used are shown in "Example 2".

[0143] Aging-related marker detection experiment ( Figure 3 ) showed that SOX5 protein levels were increased in WS mesenchymal progenitor cells infected with PLE4-SOX5 lentivirus compared with cells infected with PLE4-GAL4 ( Figure 3 The percentage of Ki67-positive cells in cells infected with PLE4-SOX5 lentivirus increased from 29.7% in PLE4-GAL4 infected cells to 52.3% ( Figure 3 B), indicating that increasing SOX5 content can promote cell proliferation. The proportion of SA-β-gal positive cells in cells infected with PLE4-SOX5 lentivirus decreased from 47.0% in PLE4-GAL4 infected cells to 20.8% ( Figure 3 In the middle C); the levels of CDKN2A, CDKN1A, IL-6 and CXCL8 were decreased, and the levels of LMNB1 and TMPO were increased in cells infected with PLE4-SOX5 lentivirus ( Figure 3 (D), indicating that increasing SOX5 content can improve the levels of aging-related markers.

[0144] Example 4: Increasing the SOX5 gene content can delay the replicative senescence of mesenchymal precursor cells

[0145] The 6th generation wild-type mesenchymal progenitor cells (obtained from the human embryonic stem cell H9 cell line) were used as test cells and infected with the PLE4-GAL4 and PLE4-SOX5 lentiviruses obtained in "Example 3" respectively. After infection with the virus. After 3-4 generations of continuous passage, the cells were collected, and the protein level of SOX5, the cell proliferation molecule marker (Ki67), the cell senescence marker (SA-β-gal), and the levels of senescence-related proteins P16, P21, Lamin B1, and LAP2 were detected. The reagent materials and detection methods used are shown in "Example 2".

[0146] Aging-related marker detection experiment ( Figure 4 ) showed that wild-type mesenchymal progenitor cells infected with PLE4-SOX5 lentivirus had increased SOX5 protein levels compared with cells infected with PLE4-GAL4 ( Figure 4 The percentage of Ki67-positive wild-type mesenchymal progenitor cells infected with PLE4-SOX5 lentivirus increased from 50.4% to 74.2% in PLE4-GAL4 infected cells ( Figure 4 B), indicating that increasing SOX5 content can promote cell proliferation. The proportion of SA-β-gal positive cells in cells infected with PLE4-SOX5 lentivirus decreased from 21.8% in PLE4-GAL4 infected cells to 14.0% ( Figure 4 Middle C); The levels of P16 and P21 in cells infected with PLE4-SOX5 lentivirus were reduced, and the levels of Lamin B1 and LAP2 were increased ( Figure 4 (D), indicating that SOX5 content can improve the levels of aging-related markers.

[0147] Example 5: Supplementation of SOX5 gene content can delay the accelerated aging phenotype of mesenchymal precursor cells carrying human progeria gene mutations

[0148] The 8th generation human progeria mesenchymal precursor cells were used as test cells and infected with the PLE4-GAL4 and PLE4-SOX5 lentiviruses obtained in "Example 3" respectively. After infection with the virus. After 3-4 generations of continuous passage, the cells were collected to detect the protein level of SOX5, the cell proliferation molecule marker (Ki67), the cell senescence marker (SA-β-gal), and the levels of senescence-related proteins P16, P21, Lamin B1, and LAP2. The reagent materials and detection methods used are shown in "Example 2". In addition, the antibody used to detect the Progerin protein, a specific marker for progeria, was produced by Santa Cruz Biotechnology, and the product number is sc-81611.

[0149] Aging-related marker detection experiment ( Figure 5 ) showed that SOX5 protein levels were increased in mesenchymal progenitor cells infected with PLE4-SOX5 lentivirus compared with cells infected with PLE4-GAL4 ( Figure 5 The percentage of Ki67-positive mesenchymal progenitor cells infected with PLE4-SOX5 lentivirus increased from 30.4% to 50.2% in PLE4-GAL4 infected cells (Figure 5A), indicating an increase in intracellular SOX5 content. Figure 5 B), indicating that increasing SOX5 content can promote cell proliferation. The proportion of SA-β-gal positive cells in cells infected with PLE4-SOX5 lentivirus decreased from 36.8% in PLE4-GAL4 infected cells to 20.7% ( Figure 5 Middle C); The levels of P16 and P21 in cells infected with PLE4-SOX5 lentivirus were reduced, and the levels of Lamin B1 and LAP2 were increased ( Figure 5 D), indicating that increasing SOX5 content can improve the levels of aging-related markers. At the same time, the level of Progerin in cells infected with PLE4-SOX5 lentivirus was reduced ( Figure 5 Middle E), indicating that increasing the SOX5 content can reduce the content of progeria markers in children.

[0150] Examples 2, 3, 4 and 5 illustrate that increasing the SOX5 content can significantly delay the pathological aging of mesenchymal precursor cells carrying human progeria gene mutations and / or adult progeria gene mutations and the replicative aging process of mesenchymal precursor cells.

[0151] Example 6: Therapeutic effect of increasing SOX5 content on age-related osteoarthritis in mice

[0152] 1. Preparation of Lentivirus Expressing Mouse SOX5

[0153] 1.1 Preparation of recombinant vectors for increasing the mouse SOX5 gene

[0154] The full-length cDNA sequence of mouse mSOX5 was amplified by PCR using the cDNA of mouse embryonic fibroblasts as a template. The amplification primers are as follows:

[0155] cDNA-mSOX5-F: 5'-ATGCTTACTGACCCTGATTTACCTCAGGAG-3';

[0156] cDNA-mSOX5-R: 5'-TCAGTTGGCTTGTCCCGCAATGTGG-3'.

[0157] The full-length cDNA sequence of mouse SOX5 obtained by PCR amplification (can also be directly synthesized, SEQ ID No. 4 in the sequence table, encoding mSOX5 shown in SEQ ID No. 5) was connected to the PLE4 vector double-digested with BamHI (NEB) and MluI (NEB), and the recombinant vector with the correct sequence was recorded as the recombinant vector PLE4-mSOX5, and PLE4-mSOX5 can express the mSOX5 shown in SEQ ID No. 5. Specifically, PLE4-mSOX5 is a recombinant vector obtained by replacing the DNA fragment between the BamHI and MluI recognition sequences of the PLE4 vector with the DNA fragment shown in SEQ ID No. 4.

[0158] According to the steps 1.1-1.4 in "Example 1-Step 1", the SAMv2 plasmid library was replaced with PLE4-mSOX5 and PLE4-GAL4 of Example 3, respectively, to obtain PLE4-mSOX5 and PLE4-GAL4 lentiviral concentrates, respectively. The lentivirus was resuspended in 1×PBS, and the virus amount in the obtained two virus solutions was equal.

[0159] 2. Establishment of osteoarthritis model in aged mice

[0160] Test mice: Male, 18-month-old SPF mice (C57BL / 6), from Beijing Biotechnology Co., Ltd. Mice were kept at 23°C, 12 hours of light / 12 hours of darkness, free access to food and water. Experimental equipment and materials included: isoflurane gas anesthesia apparatus, insulin syringe.

[0161] 2.1 Group Processing

[0162] In the PLE4-mSOX5 group (11 mice), 20 μl of PLE4-mSOX5 lentiviral suspension was injected into the left and right joint cavities of the hind limbs of each mouse.

[0163] In the PLE4-GAL4 group (11 mice), 20 μl of PLE4-GAL4 lentiviral suspension was injected into the left and right joint cavities of the hind limbs of each mouse.

[0164] 3. Effect evaluation

[0165] Eight weeks after the injection of the lentiviral suspension, the therapeutic effect was evaluated ( Figure 6 The specific method is as follows:

[0166] 3.1 Behavioral evaluation of changes in joint mobility of mice

[0167] Eight weeks after the injection of the lentivirus suspension, the joint mobility of the mice was evaluated by testing the grip strength of their hind limbs: using a grip strength tester. The mouse trunk was kept parallel to the grid, and after its hind limbs grasped the tester, the tail of the mouse was grasped and pulled back evenly, and the maximum grip strength value was recorded. Each mouse was repeated 10 times, and the average value was taken as the grip strength value of the mouse.

[0168] The results showed that the grasping force of mice injected with PLE4-mSOX5 lentiviral suspension increased ( Figure 6 Middle B) shows that the joint mobility of mice injected with PLE4-mSOX5 lentiviral suspension was improved.

[0169] After completing the behavioral assessment, the mice were killed by spinal dislocation and the hind limb knee joints were isolated. After removing the muscle tissue from the left knee joint, 1 cm of the femur and tibia were retained for CT examination and tissue embedding staining. The right knee joint cartilage was stripped to extract RNA and detect the transcription level of related genes.

[0170] 3.2 CT Scan

[0171] Mouse joints fixed in 4% paraformaldehyde were scanned using a small animal CT (Quantum GX2) at 52 kVp, 100 μA, and a resolution of 36 μm. Osteophyte volume was analyzed using Analyze (V14.0) and Slicer (V5.2) software.

[0172] Compared with mice injected with PLE4-GAL4 lentivirus suspension, mice injected with PLE4-mSOX5 lentivirus suspension had reduced osteophyte volume in their joints ( Figure 6 (D) This indicates that supplementing SOX5 in the joint cavity helps inhibit bone hyperplasia.

[0173] 3.3 Mouse articular cartilage staining

[0174] 3.3.1 Cartilage Safranin Fast Green Staining

[0175] (1) After dewaxing and rehydration, the sections were stained with fresh hematoxylin solution at room temperature for 3-5 minutes.

[0176] (2) After differentiation for 15 seconds, wash with distilled water for 10 minutes.

[0177] (3) Place in Fast Green staining solution and stain for 5 minutes at room temperature.

[0178] (4) Quickly rinse with a weak acid solution for 10-15 seconds to remove the remaining fast green and dry.

[0179] (5) Place in safranin staining solution and stain for 5 minutes at room temperature.

[0180] (6) Dehydration, transparency, and sealing.

[0181] (7) Scan and count.

[0182] Compared with mice injected with PLE4-GAL4 lentivirus suspension, mice injected with PLE4-mSOX5 lentivirus suspension had increased cartilage area ( Figure 6 Middle E). This indicates that increasing the content of SOX5 in cartilage tissue helps promote cartilage thickening.

[0183] 3.3.2 Cartilage hematoxylin and eosin staining (HE staining)

[0184] (1) After dewaxing and rehydration, the sections were stained with fresh hematoxylin solution at room temperature for 3-5 minutes.

[0185] (2) After differentiation for 15 seconds, wash with distilled water for 10 minutes.

[0186] (3) Place in eosin staining solution and stain for 5 minutes at room temperature.

[0187] (4) Rinse with clean water for 2 minutes.

[0188] (5) Dehydration, transparency, and sealing.

[0189] (6) Scan and count.

[0190] (7) The synovial score is calculated by measuring the thickness or number of synovial cells in the joint. The scoring criteria are as follows:

[0191] 0 = single synovium or no more than 3 cell layers; 1 = synovium with 5–10 cell layers; 2 = synovium with more than 10 cell layers.

[0192] Compared with mice injected with PLE4-GAL4 lentiviral suspension, mice injected with PLE4-mSOX5 lentiviral suspension had reduced synovial thickness ( Figure 6 (F) This indicates that supplementing SOX5 in the joint cavity helps inhibit synovial hyperplasia.

[0193] 3.3.3 Immunohistochemical staining

[0194] (1) The left knee joint of mice was placed in 4% paraformaldehyde solution and fixed at 4°C for 2 days.

[0195] (2) Use a decalcification solution containing 5% formic acid at 4°C until the femoral and tibial tissues soften and can be punctured with a needle (approximately 7-10 days).

[0196] (3) Embed in paraffin, slice to a thickness of 5 μm, and bake at 60°C overnight.

[0197] (4) Dewax and rehydrate the sections.

[0198] (5) Use 0.125% trypsin (ZLI-9010) to repair the antigen and incubate at 37°C for 30 minutes.

[0199] (6) Permeabilize with 0.4% Triton X-100 (Sigma-Aldrich, T9284) at room temperature for 1 hour.

[0200] (7) Use an endogenous peroxidase blocker to block endogenous peroxidase.

[0201] (8) After washing with PBS at room temperature, add primary antibody and incubate at 4°C overnight.

[0202] (9) Wash three times with PBS at room temperature.

[0203] (10) Add reaction enhancement solution and incubate at room temperature for 20 minutes.

[0204] (11) Wash thoroughly with PBS at room temperature for 20 min each time, for a total of 3 times.

[0205] (12) Add enhanced enzyme-labeled goat anti-mouse / rabbit IgG polymer and incubate at room temperature for 1 hour.

[0206] (13) Select an appropriate time for DAB color development.

[0207] (14) Hematoxylin staining, differentiation and washing, and blueing.

[0208] (15) Dehydrate, transparentize, and seal the slides.

[0209] (16) The images were scanned using a PE panoramic scanner (PerkinElmer Vectra Polaris), and the proportion of positive cells in the cartilage layer was counted using Image J.

[0210] The antibody used to detect SOX5 protein was produced by Abcam, with the catalog number ab94396.

[0211] The antibody used to detect P21 protein was produced by Cell Signaling Technology, and the product number is 2947S.

[0212] The antibody used to detect MMTV protein was produced by Novus Biologicals, with the catalog number NBP2-44179.

[0213] The antibody used to detect IL-6 protein was produced by Abcam, with the catalog number ab6672.

[0214] The antibody used to detect TNFα protein was produced by Abcam, with the catalog number ab1793.

[0215] The antibody used to detect MMP13 protein was produced by Abcam, with the catalog number ab39012.

[0216] The antibody used to detect Aggrecan protein was produced by ABclonal, with the product number A11691.

[0217] Compared with mice injected with PLE4-GAL4 lentivirus suspension, the content of SOX5 in the cartilage tissue of mice injected with PLE4-mSOX5 lentivirus suspension increased ( Figure 6 C), indicating that the PLE4-mSOX5 lentiviral suspension was injected into the joint cavity and successfully infected chondrocytes. It was found that the number of P21 and MMTV positive cells decreased ( Figure 6 G, H), IL-6 and TNFα positive cells decreased ( Figure 6 I, J), indicating that the content of SOX5 was supplemented in the joint cavity, and the senescent cells and inflammatory cells in the cartilage tissue decreased. In addition, the proportion of cells secreting Aggrecan increased ( Figure 6 K), while the proportion of cells secreting matrix metalloproteinase MMP13 decreased ( Figure 6 Middle L), indicating that replenishing the content of SOX5 in the joint cavity maintains the function of chondrocytes to secrete extracellular matrix.

[0218] 3.3.4 RT-qPCR detection of genes related to articular cartilage inflammation and regeneration

[0219] Firstly, the right knee cartilage tissues of the two groups of mice were lysed with TRIZOL (Invitrogen, 15596018), and RNA was extracted and then reverse transcribed into cDNA. RT-qPCR was used to detect the transcript levels of inflammatory response-related genes (Cd5l, Ccr2), NF-κB signaling pathway-related genes (S100a8, S100a9), regeneration-related genes (Yap1), cartilage development-related genes (Sox9, Acan) and extracellular matrix-related genes (Col2a1, Col11a1).

[0220] Primers for detecting mRNA levels of Cd5l, Ccr2, S100a8, S100a9, Yap1, Sox9, Acan, Col2a1, and Col11a1 are as follows:

[0221] Cd5l-F: 5′-CAGGCTGGAACTTACAGGTCT-3′; Cd5l-R: 5′-GTCCTTTGCCCTGAGTATTCTTG-3′;

[0222] Ccr2-F: 5′-ATCCACGGCATACTATCAACATC-3′; Ccr2-R: 5′-CAAGGCTCACCATCATCGTAG-3′;

[0223] S100a8-F: 5′-AAATCACCATGCCCTCTACAAG-3′; S100a8-R: 5′-CCCACTTTTATCACCATCGCAA-3′;

[0224] S100a9-F: 5′-GCACAGTTGGCAACCTTTATG-3′; S100a9-R: 5′-TGATTGTCCTGGTTTGTGTCC-3′;

[0225] Yap1-F: 5′-TGAGATCCCTGATGATGTACCAC-3′; Yap1-R: 5′-TGTTGTTGTCTGATCGTTGTGAT-3′;

[0226] Sox9-F: 5′-CAGCCCCTTCAACCTTCCTC-3′; Sox9-R: 5′-TGATGGTCAGCGTAGTCGTATT-3′;

[0227] Acan-F: 5′-CCTGCTACTTCATCGACCCC-3′; Acan-R: 5′-AGATGCTGTTGACTCGAACCT-3′;

[0228] Col2a1-F: 5′-GGGTCACAGAGGTTACCCAG-3′; Col2a1-R: 5′-GGGTCACAGAGGTTACCCAG-3′;

[0229] Col11a1-F: 5′-GGTGGAAAACGAAACGGTGG-3′; Col11a1-R: 5′-TCTGACCTCTCTAGCTTGGAAG-3′.

[0230] The results showed that in the cartilage tissue of mice injected with PLE4-mSOX5 lentiviral suspension, the transcription levels of inflammatory response-related genes (Cd5l, Ccr2) and NF-κB signaling pathway-related genes (S100a8, S100a9) were reduced ( Figure 6 M), while the transcription levels of regeneration-related genes (Yap1), cartilage development-related genes (Sox9, Acan) and extracellular matrix-related genes (Col2a1, Col11a1) were increased ( Figure 6N in the middle), which is consistent with the transcript sequencing results. This shows that supplementing the content of SOX5 reduces the level of cartilage inflammation and improves the biological activity of cartilage tissue cells.

[0231] Example 7: Therapeutic effect of increasing SOX5 content on mouse ACLT osteoarthritis model

[0232] 1. Establishment of injury-induced osteoarthritis model in mice

[0233] Test mice: male, 2-month-old SPF mice (C57BL / 6), from Beijing Biotechnology Co., Ltd. Mice were kept at 23°C, 12 hours of light / 12 hours of darkness, free access to food and water. Experimental equipment and materials included: isoflurane gas anesthesia apparatus, insulin syringe.

[0234] After the mice were anesthetized and fixed, the skin around the knee joint of the hind limbs was depilated and disinfected. Then, the skin and joint capsule were cut along the inner side of the patellar ligament to expose the knee joint cavity, the knee joint was flexed 90°, and the anterior cruciate ligament was cut. After flushing with saline and stopping bleeding, suture was performed. After confirming that there was no further bleeding, the mice were returned to the cage and raised normally to obtain a mouse injury-induced osteoarthritis model. Lentivirus injection was performed 8-10 days later.

[0235] Group processing:

[0236] ACLT sham operation group (12 mice), the skin of the left and right joints of the hind limbs of each C57BL / 6 mouse was cut and sutured ( Figure 7 (A).

[0237] In the ACLT-PLE4-mSOX5 group (12 mice), 20 μl of PLE4-mSOX5 lentiviral suspension was injected into the left and right joint cavities of the hind limbs of each mouse in the injury-induced osteoarthritis model.

[0238] In the PLE4-GAL4 group (12 mice), 20 μl of PLE4-GAL4 lentiviral suspension was injected into the left and right joint cavities of the hind limbs of each mouse in the injury-induced osteoarthritis model.

[0239] 2. Effect evaluation

[0240] Eight weeks after lentivirus injection, mice were killed by spinal dislocation and the hind knee joints were isolated. After removing muscle tissue from the left knee joint, 1 cm of femur and tibia were retained for CT examination and tissue embedding staining. The right knee joint cartilage was stripped to extract RNA and detect the transcription level of related genes.

[0241] According to the results of SO&FG staining, cartilage damage was scored by the Osteoarthritis Research Society International (OARSI). The scoring criteria are as follows:

[0242] 0 = normal;

[0243] 1 = slight wear of the cartilage surface, with the damaged area less than 5% of the total area;

[0244] 2 = partial loss of cartilage surface matrix, not involving the deep cartilage, with the damaged area accounting for about 5%–10% of the total area;

[0245] 3 = The lesion involves the calcified cartilage layer, and the damaged area accounts for about 10%–24% of the total area;

[0246] 4 = lesions extending below the calcified cartilage, with more than 25%–50% cartilage loss over the joint surface;

[0247] 5 = 50%–75% cartilage loss of the joint surface;

[0248] 6 = Loss of greater than 75% of the cartilage on the joint surface, with possibly only a few areas of acellular collagen remaining.

[0249] Compared with mice injected with PLE4-GAL4 lentivirus suspension, the proportion of SOX5-positive cells in the articular cartilage of mice injected with PLE4-mSOX5 lentivirus suspension increased ( Figure 7 Middle B), indicating that the PLE4-mSOX5 lentivirus suspension was injected into the joint cavity and successfully infected the chondrocytes. CT scans showed that the volume of osteophyte hyperplasia in the joints of mice injected with the PLE4-mSOX5 lentivirus suspension was reduced ( Figure 7 C). This indicates that supplementing the content of SOX5 in the joint cavity helps inhibit osteophyte proliferation. Safranin fast green staining showed that the degree of cartilage injury (OARSI) of mice injected with PLE4-mSOX5 lentivirus suspension was reduced ( Figure 7 D). This indicates that increasing the content of SOX5 in cartilage tissue helps promote cartilage integrity. HE staining showed that the synovial thickness of mice injected with PLE4-mSOX5 lentivirus suspension was reduced ( Figure 7 Middle E). This indicates that supplementing SOX5 into the joint cavity helps inhibit synovial hyperplasia.

[0250] Immunohistochemical staining showed that compared with mice injected with PLE4-GAL4 lentivirus suspension, the proportion of cells secreting Aggrecan in the cartilage tissue of mice injected with PLE4-mSOX5 lentivirus suspension increased ( Figure 7 F), while the proportion of cells secreting matrix metalloproteinase MMP13 decreased ( Figure 7Middle G), indicating that the content of SOX5 in the joint cavity is supplemented to maintain the function of chondrocytes to secrete extracellular matrix. In addition, the number of IL-6 positive cells decreased ( Figure 7 Middle H) indicates that the content of SOX5 was supplemented in the joint cavity and the inflammatory cells in the cartilage tissue were reduced.

[0251] Example 7 illustrates that supplementing the content of SOX5 in the joint cavity alleviates the cartilage damage of pathological osteoarthritis, reduces the level of joint inflammation, and improves the biological activity of cartilage tissue cells.

[0252] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.

Claims

1. Use of SOX5 or substances that increase the content or activity of SOX5 in the preparation of products for treating and / or preventing and / or delaying aging.

2. The use according to claim 1, characterized in that: The substance that increases the content or activity of SOX5 is a substance that promotes the expression of the SOX5 gene or a biological material related to SOX5; The biological material is any one of the following B1) to B4): B1) Nucleic acid molecule encoding SOX5; B2) an expression cassette containing the nucleic acid molecule described in B1); B3) a recombinant vector containing the nucleic acid molecule described in B1), or a recombinant vector containing the expression cassette described in B2); B4) A recombinant microorganism containing the nucleic acid molecule described in B1), or a recombinant microorganism containing the expression cassette described in B2), or a recombinant microorganism containing the recombinant vector described in B3).

3. The use according to claim 2, characterized in that: The substance that promotes SOX5 gene expression is a CRISPR / dCas9 transcription activation system that targets the transcription start site of the SOX5 gene.

4. The use according to any one of claims 1 to 3, characterized in that: The substance that increases the content or activity of SOX5 is a SOX5 agonist.

5. The use according to any one of claims 1 to 4, characterized in that: The aging is replicative aging, and / or pathological aging of adult progeria or childhood progeria.

6. The use according to any one of claims 1 to 5, characterized in that: The aging is the aging of animal cells, tissues, organs or individuals; Further, the tissue is cartilage tissue; And / or, the treatment and / or prevention of aging is reflected in promoting cell proliferation and / or reducing inflammation levels and / or improving the expression of aging markers, aging-related genes, SASP-related genes and / or progeria markers.

7. Use of SOX5 or a substance that increases the content or activity of SOX5 according to any one of claims 1 to 4 in the preparation of a product that increases the biological activity of animal cells, tissues, organs or individuals.

8. The use according to claim 7, characterized in that: The tissue is cartilage tissue; And / or, the improvement in biological activity is reflected in the improvement of animal athletic ability, the reduction of senescent cells and / or inflammatory cells, the increase of cartilage thickness, the increase of expression of genes promoting cartilage development, collagen and proteoglycan formation, regeneration-related genes, cartilage development-related genes and extracellular matrix-related genes, and / or the decrease of expression of genes in immune response regulation, NF-κB and oxidative stress-related signaling pathways.

9. Use of SOX5 or a substance that increases the content or activity of SOX5 according to any one of claims 1 to 4 in the preparation of a product for treating aging-related degenerative diseases.

10. The use according to claim 9, characterized in that: The aging-related degenerative disease is osteoarthritis.

11. A product, wherein the active ingredient is SOX5 or a substance that increases the content or activity of SOX5 as claimed in any one of claims 1 to 4.